Phenylpiracetam: what does this study show?
90 patients in a double-blind, randomized, placebo-controlled add-on study. Reported doses were 100 or 200 mg; schedule, route and duration are not stated in the English abstract.
The report describes lower seizure frequency and improved cognition in patients without epileptiform EEG abnormalities. It did not reduce negative effects of standard antiseizure treatment in 40% of patients.
The abstract does not give numerical between-group effect sizes. Add-on epilepsy findings do not establish general cognitive enhancement.
These findings apply to the population and methods described above.
What might this mean, and what would change the interpretation?
The abstract does not give numerical between-group effect sizes. Add-on epilepsy findings do not establish general cognitive enhancement.
What would clarify this: Independent replication with clinically meaningful outcomes and longer safety follow-up.
Findings reviewed · abstract
Checked Sep 23, 2026 against the linked abstract. This reading note is not a formal risk-of-bias appraisal.